More recently GPC-3 in HCC has been used as a target in chimeric antigen receptor, or CAR T-cell therapy (245, 246, 263), with the therapy demonstrating the ability to reduced HCC tumors in a xenograft model (245). Here, GPC3 is linked to hepatocellular carcinoma.